A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.

Trial Details

NCT ID
NCT06927466
Phase
PHASE1
Sponsor
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • B019
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Nanchang, China|28.68396,115.85306
  • Nanchang, China|28.68396,115.85306
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • The patient himself/herself , and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form；
  • Meet the diagnostic criteria for recurrent or refractory acute B cell lymphoblastic leukemia；
  • Documentation of CD19/CD22 tumor expression
  • 3\. Liver, kidney, lung and heart function meet requirements; 4. Expected survival \>3 months; 5. Women of childbearing age and all post-adolescent…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →